CO-TEKNOWLEDGE
TeKnowledge marks its global debut today, bringing together the formidable strengths of Cytek Security, Tek Experts, and Elev8 into a single, unified powerhouse. Each entity contributes its specialized expertise—Cytek Security in cutting-edge cybersecurity readiness, Tek Experts in unparalleled enterprise technical managed services, and Elev8 in innovative technical skilling—creating a comprehensive portfolio under TeKnowledge that offers end-to-end digital transformation services. This strategic amalgamation heralds the beginning of a new era in tech services, where TeKnowledge stands as the transformative catalyst for digital evolution, providing governments and enterprises worldwide with unparalleled cybersecurity services, advanced technical skilling, and enterprise technical managed services at scale.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240409688971/en/
TeKnowledge: Uniting Cytek Security, Tek Experts, and Elev8 under one banner to pioneer the future of secure digital transformation and tech talent empowerment across the globe (Graphic: Business Wire)
Backed by over a decade of pioneering achievements in the tech services industry and a distinguished roster of government and enterprise customers worldwide, TeKnowledge is uniquely equipped to navigate the complexities of digital modernization. By integrating these powerhouse brands, TeKnowledge tackles the critical challenges of bridging the tech talent gap and expediting digital imperatives, providing a holistic suite of services tailored to bolster cybersecurity defenses, cultivate essential technical skills, and deliver expert technical managed services to streamline and accelerate digital strategies.
Under the guidance of Aileen Allkins, President and CEO, TeKnowledge is pioneering new frontiers in digital services. Drawing upon her notable success at various tech giants including Microsoft and HP, Aileen has swiftly positioned TeKnowledge as a leader in secure and scalable technology solutions. In her first strategic initiative, Aileen has built an exceptional leadership team, merging seasoned executives from Tek Experts, Elev8, and Cytek, and enriched by strategic new appointments. This includes bringing on board Jyllene Miller as Chief Revenue and Growth Officer, tapping into her extensive experience in growth strategies and market development garnered at numerous Fortune 500 companies to propel TeKnowledge's global expansion. The team is further bolstered by Eric Schifflers as Chief Information Security Officer (CISO), whose vast experience across global organizations like NATO, Ria Money Transfer, and Roche, amplifies TeKnowledge's cybersecurity defenses and strategic security initiatives.
The executive leadership team at TeKnowledge, a dynamic group of seasoned leaders, embodies a wealth of diverse expertise, driving the company's strategic vision across public and private sectors. Their collective skills in global operations, cybersecurity, digital transformation, and customer experience, honed over decades, are crucial in navigating the digital landscape's complexities. This team's unified approach is setting new industry standards, establishing TeKnowledge as a leader in digital services and a catalyst for transformative growth and resilience in the digital era.
"A unified TeKnowledge signifies a major shift in digital transformation services," states Aileen Allkins, President and CEO. "Bringing together the expertise of Cytek Security, Tek Experts, and Elev8 under the TeKnowledge umbrella, creates a synergy that benefits our customers as we enhance our delivery, achieving faster, more impactful outcomes. This positions us to effectively tackle the tech talent gap and pace of digital innovation. Offering a comprehensive suite of elite cybersecurity services, top-tier digital skilling, and scalable technical managed services, TeKnowledge is committed to guiding governments and enterprises worldwide through the complexities of digital transformation. Our approach integrates these services seamlessly, maximizing efficiency, simplifying processes, and accelerating the achievement of strategic imperatives with unparalleled precision and efficacy."
How TeKnowledge is Bridging Global Divides with Local Impact:
- Optimized Managed Technical Services: TeKnowledge (f.k.a. Tek Experts) stands out with its superior operational excellence and agile solutions, supported by a global network of professionals, including a significant presence in emerging markets. Our enterprise managed services are distinguished by their ability to seamlessly integrate and scale, ensuring organizations achieve operational superiority and strategic success in the digital landscape.
- Precision Technical Skilling: Directly addressing the global talent gap, TeKnowledge's (f.k.a. Elev8) custom training programs are strategically designed to equip both the current and future generations with the skills needed to navigate and excel in the ever-evolving tech landscape, preparing them for the challenges and opportunities that lie ahead.
-
Dynamic Cybersecurity Services: With an all-encompassing suite of advisory and Managed Security Services (MSS) offerings, TeKnowledge (f.k.a. Cytek Security) equips customers with dynamic defenses against the evolving cyber landscape.
The launch of TeKnowledge heralds an important evolution in the global digital landscape, emphasizing a future where digital security and operational excellence transform from aspirations into baseline expectations worldwide. At the core of this transformation is the robust talent—engineers supporting engineers, and developers supporting developers—to ensure unparalleled expertise and collaboration in tackling the digital challenges ahead.
To learn more about TeKnowledge, visit www.TeKnowledge.com.
About TeKnowledge: Accelerating Progress, Securing Futures.
TeKnowledge stands as the transformative catalyst for digital evolution, enabling governments and enterprises worldwide to navigate the challenges with digital transformation today and tomorrow with elite cybersecurity implementation and managed security services (MSS), top-tier digital skilling, and technical managed services at scale. TeKnowledge envisions a world where every government and enterprise is empowered with the most advanced, secure, and accessible technology solutions. Our commitment to technology enablement, security, and advancement positions us uniquely in the market, ensuring our customers are equipped to achieve their strategic imperatives in the digital age with confidence and competitive advantage. Start your journey towards digital excellence by visiting TeKnowledge.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240409688971/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom